VIRI
Undervalued by 14% based on the discounted cash flow analysis.
Market cap | $206,502.00 |
---|---|
Enterprise Value | $-2,813,681.00 |
Dividend Yield | $0 (0%) |
Earnings per Share | $-0.28 |
Beta | 1.58 |
Outstanding Shares | 22,900,794 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -0.76 |
---|---|
PEG | 2.79 |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | - |
Enterprise Value to EBIT | 0.46 |
Enterprise Value to Net Income | 0 |
Total Debt to Enterprise | 0 |
Debt to Equity | 0 |
No data
No data
Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ('FM'). Overactive immune ...